These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 6937949)

  • 21. Cefamandole in the treatment of serious bone and joint diseases.
    Levine LR
    Scand J Infect Dis Suppl; 1980; suppl 25():89-93. PubMed ID: 7010542
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bacteriology and antibiotic susceptibility of community-acquired intra-abdominal infection in children.
    Lin WJ; Lo WT; Chu CC; Chu ML; Wang CC
    J Microbiol Immunol Infect; 2006 Jun; 39(3):249-54. PubMed ID: 16783457
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Activity of cephazolin and other cephalosporins against Bacteroides fragilis.
    Leigh DA; Simmons K
    Scott Med J; 1976 Sep; 20(5):228-31. PubMed ID: 1265472
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Interactions between aerobic and anaerobic bacteria.
    Gorbach SL
    Scand J Infect Dis Suppl; 1982; 31():61-7. PubMed ID: 6954639
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antibiotic use in neonatal sepsis.
    Yurdakök M
    Turk J Pediatr; 1998; 40(1):17-33. PubMed ID: 9722468
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro activity of ertapenem: review of recent studies.
    Wexler HM
    J Antimicrob Chemother; 2004 Jun; 53 Suppl 2():ii11-21. PubMed ID: 15150179
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antimicrobial activity of SMAP-29 against the Bacteroides fragilis group and clostridia.
    Arzese A; Skerlavaj B; Tomasinsig L; Gennaro R; Zanetti M
    J Antimicrob Chemother; 2003 Sep; 52(3):375-81. PubMed ID: 12917245
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vitro bactericidal activities and morphologic changes in Escherichia coli and Bacteroides fragilis by cephalosporins.
    Mikamo H; Kawazoe K; Sato Y; Hayasaki Y; Satoh M; Kai J; Tamaya T
    Chemotherapy; 1998; 44(3):157-63. PubMed ID: 9612605
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cefotaxime in the treatment of prophylaxis of surgical infections.
    Wittmann DH; Jones RN; Malledant J; Privitera G
    J Chemother; 1997 May; 9 Suppl 2():19-33. PubMed ID: 9248973
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The antimicrobial activity of cefamandole.
    Meyers BR
    Scand J Infect Dis Suppl; 1980; suppl 25():17-22. PubMed ID: 6937948
    [No Abstract]   [Full Text] [Related]  

  • 31. [Review of oral cephalosporins. Basis for a rational choice].
    Forti IN
    Medicina (B Aires); 1994; 54(5 Pt 1):439-58. PubMed ID: 7658980
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Multicentre survey of the in-vitro activity of seven antimicrobial agents, including ertapenem, against recently isolated Gram-negative anaerobic bacteria in Greece.
    Papaparaskevas J; Pantazatou A; Katsandri A; Legakis NJ; Avlamis A;
    Clin Microbiol Infect; 2005 Oct; 11(10):820-4. PubMed ID: 16153256
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vitro activity of cefaclor against aerobic and anaerobic bacteria.
    Bach VT; Khurana MM; Thadepalli H
    Antimicrob Agents Chemother; 1978 Feb; 13(2):210-3. PubMed ID: 646343
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anaerobic sepsis due to multidrug-resistant Bacteroides fragilis: microbiological cure and clinical response with linezolid therapy.
    Wareham DW; Wilks M; Ahmed D; Brazier JS; Millar M
    Clin Infect Dis; 2005 Apr; 40(7):e67-8. PubMed ID: 15824978
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The treatment of serious anaerobic infections.
    Greenberg RN; Scalcini MC; Sanders CV; Lewis AC
    Scand J Infect Dis Suppl; 1980; suppl 25():84-8. PubMed ID: 7010541
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inducible metronidazole resistance in nim-positive and nim-negative bacteroides fragilis group strains after several passages metronidazole containing columbia agar plates.
    Schaumann R; Petzold S; Fille M; Rodloff AC
    Infection; 2005 Oct; 33(5-6):368-72. PubMed ID: 16258869
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of obstetric and gynecologic infections with cefamandole.
    Cunningham FG; Gilstrap LC; Kappus SS
    Am J Obstet Gynecol; 1979 Mar; 133(6):602-10. PubMed ID: 426015
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cefepime.
    Hardin TC; Jennings TS
    Pharmacotherapy; 1994; 14(6):657-68. PubMed ID: 7885968
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Infection with Bacteroides fragilis: pathogenesis and immunoprophylaxis in an animal model.
    Kasper DL; Onderdonk AB
    Scand J Infect Dis Suppl; 1982; 31():28-33. PubMed ID: 6954635
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Activity of cephamandole against some gram-negative bacilli and staphylococci.
    Dzierzanowska D; Jakubicz P; Niedźwiecka M; Borowski J
    Arch Immunol Ther Exp (Warsz); 1980; 28(3):389-91. PubMed ID: 6969585
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.